Le Lézard
Classified in: Health, Science and technology
Subject: FDA

Intralytix Receives FDA Regulatory Clearance for Phage-Based Shigella Technology


BALTIMORE, April 7, 2017 /PRNewswire/ -- Intralytix, Inc. announced today that its latest food safety product, ShigaShieldtm, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA).

ShigaShieldtm is a non-chemical antimicrobial preparation for controlling the foodborne/waterborne bacterial pathogen Shigella. The active ingredients of ShigaShieldtm are naturally occurring lytic bacteriophages that selectively and specifically kill Shigella species, including strains belonging to the three major disease-causing species of Shigella: S. flexneri, S. sonnei and S. dysenteriae.

"Shigella is one of the leading bacterial causes of diarrhea worldwide, causing an estimated 80-165 million cases each year," stated Dr. Alexander Sulakvelidze, Intralytix's Chief Scientist. "In the United States, Shigella is the third most common causes of gastroenteritis, with more than 500,000 cases occurring annually. ShigaShieldtm can help reduce the incidence or severity of such illnesses." Dr. Sulakvelidze added, "Another important potential application is to use ShigaShieldtm for improving the safety of foods for the US military and for travelers; for example, for treating fresh fruits and vegetables in high risk Shigella locations oversees where the local sanitation standards and/or quality of water are not optimal, thus creating an increased risk of Shigella contamination."

Intralytix is a world leader in the development of bacteriophage-based products for food safety. The company already has three FDA/USDA approved phage-based products on the market: (1) ListShieldtm, effective at substantially reducing or eliminating Listeria monocytogenes in food products, (2) EcoShieldtm, effective at substantially reducing or eliminating E. coli O157:H7 in red meat intended for grinding, and (3) SalmoFreshtm, effective at substantially reducing or eliminating Salmonella in poultry, fish, shellfish, and fresh and processed fruits and vegetables.

Intralytix, Inc is a biotechnology company focused on using its core bacteriophage/phage technology platform to improve human health through the development and commercialization of innovative products for food safety, animal health and human therapeutics and probiotics.

For more information, contact Mr. John Woloszyn (410-625-3813 or [email protected]) or Dr. Alexander Sulakvelidze (410-625-2533 or [email protected]).

Intralytix, Inc.
Columbus Center
701 E. Pratt Street
Baltimore, Maryland 21202
Safety by Naturetm
Web site: www.Intralytix.com
1-877-ITXPHAGE (1-877-489-7424)

This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com.

 

SOURCE Intralytix, Inc.


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: